Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: A retrospective cohort study

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Zilberberg, Marya D ^a,b   Reske, Kimberly ^c   Olsen, Margaret ^c   Yan, Yan ^c   Dubberke, Erik R ^c  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b EviMed Research Group LLC   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C. difficile; Recurrence; Risk factors

Indexed keywords

METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGE; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; DISEASE PREDISPOSITION; FEMALE; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; STOMACH ACID; TREATMENT OUTCOME; ADOLESCENT; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; EVALUATION STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTOCLOSTRIDIUM DIFFICILE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; CROSS INFECTION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84902169955     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-306     Document Type: Article

References (28)

1. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472. 10.1503/cmaj.1041104, 514643, 15337727.
2. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006, 12:409-415. 10.3201/eid1205.051064, 3291455, 16704777.
3. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008, 14:929-931. 10.3201/eid1406.071447, 2600276, 18507904.
4. Lucado, J. (Social & Scientific Systems), Gould, C. (CDC), and Elixhauser, A. (AHRQ) Clostridium difficile Infections (CDI) in Hospital Stays, 2009. HCUP Statistical Brief #124. 2012, Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.jsp, Lucado, J. (Social & Scientific Systems), Gould, C. (CDC), and Elixhauser, A. (AHRQ).
5. Clements AC, Magalhaes RJ, Tatem AJ, Paterson DL, Riley TV. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Incect Dis 2010, 10:395-404.
6. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455. 10.1086/651706, 20307191.
7. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008, 70:298-304. 10.1016/j.jhin.2008.08.012, 18951661.
8. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, . OPT-80-003 Clinical Study Group Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431. 10.1056/NEJMoa0910812, 21288078, OPT-80-003 Clinical Study Group.
9. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, . OPT-80-004 Clinical Study Group Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012, 12:281-289. 10.1016/S1473-3099(11)70374-7, 22321770, OPT-80-004 Clinical Study Group.
10. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997, 24:324-333. 10.1093/clinids/24.3.324, 9114180.
11. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999, 20:43-50. 10.1086/501553, 9927265.
12. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007, 64:2359-2363. 10.2146/ajhp060629, 17989446.
13. Kim JW, Lee KL, Jeong JB, Kim BG, Shin S, Kim JS, Jung H, Son IS. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol 2010, 16:3573-3577. 10.3748/wjg.v16.i28.3573, 2909558, 20653067.
14. Zilberberg MD, Tabak YP, Sievert DM, Derby KG, Johannes RS, Sun X, McDonald LC. Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals. Infect Control Hosp Epidemiol 2011, 32:649-655. 10.1086/660360, 21666394.
15. Eyre DW, Walker AS, Wylie D, Dingle KE, Griffiths D, Finney J, Oconnor L, Vaughan A, Crook DW, Wilcox MH, Peto TE. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012, 55:S77-S87. 10.1093/cid/cis356, 3388024, 22752869.
16. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007, 28:140-145. 10.1086/511798, 17265394.
17. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007, 45:1543-1549. 10.1086/523582, 18190314.
18. Dubberke ER, Yan Y, Reske KA, Butler AM, Doherty J, Pham V, Fraser VJ. Development and validation of a Clostridium difficile infection risk prediction model. Infect Control Hosp Epidemiol 2011, 32:360-366. 10.1086/658944, 3649761, 21460487.
19. Hosmer DW, Lemeshow S. Applied Logistic Regression 2000, New York, NY: John Wiley and Sons, Inc, New York, NY, 2.
20. Harrell FE, Margolis PA, Gove S, Mason KE, Mulholland EK, Lehmann D, Muhe L, Gatchallan S, Eichenwald HF. Development of a clinical prediction model for an ordinal outcome: the World Health Organization Multicentre Study of Clinical Signs and Etiological agents of Pneumonia, Sepsis and Meningitis in Young Infants. WHO/ARI Young Infant Multicentre Study Group. Stat Med 1998, 17:909-944. 10.1002/(SICI)1097-0258(19980430)17:8<909::AID-SIM753>3.0.CO;2-O, 9595619.
21. SAS Copyright (c) 2002-2010 Cary, NC, USA: SAS Institute Inc, SAS.
22. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol 2012, 46:397-400. 10.1097/MCG.0b013e3182431d78, 22298089.
23. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenetrol 2012, 107:1011-1019.
24. Tleyjeh IM, Abdulhak AB, Riaz M, Garbati MA, Al-Tannir M, Alasmari FA, Alghamdi M, Khan AR, Erwin PJ, Sutton AJ, Baddour LM. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLoS One 2013, 8:e56498. 10.1371/journal.pone.0056498, 3587620, 23469173.
25. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011, 53:440-447. 10.1093/cid/cir404, 3156139, 21844027.
26. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260. 10.1086/496986, 16206099.
27. Petrella LA, Sambol SP, Chenknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN. Decreased cure and increased recurrence rates for Clostridium difficile Infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012, [Epub ahead of print].
28. Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidemiol 2010, 31:21-27. 10.1086/649016, 19929371.